Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3774_Библиотеки_им_академика_М_И_Перельмана
.pdf
Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
16
Table 16.2 1990 criteria for the classication of giant cell (temporal) arteritisa [5]
1. Age at disease onset
≥50years
New headache New onset of or new type of localized pain in the head
2.
3.
Temporal artery
abnormality
4. Elevated erythrocyte
sedimentation rate
Abnormal artery
5.
biopsy
a
For purposes of classication, a patient shall be said to have giant cell (temporal) arteritis if at
least 3 of these 5 criteria are present. The presence of any 3 or more criteria yields a sensitivity of
93.5% and a specicity of 91.2%
Fig. 16.1 Giant cell
arteritis. Histological
section taken from
temporal artery biopsy
shows marked intimal
thickening with luminal
stenosis associated with
dense inltrate of
lymphocytes, histiocytes,
and eosinophils, extending
to the internal elastic
lamina of the media. Only
very occasional giant cells
are seen
Development of symptoms or ndings beginning at age 50 or older
Temporal artery tenderness to palpation or decreased pulsation,
unrelated to arteriosclerosis of cervical arteries
Erythrocyte sedimentation rate≥50mm/h by the Westergren method
Biopsy specimen with artery showing vasculitis characterized by a
predominance of mononuclear cell inltration or granulomatous
inammation, usually with multinucleated giant cells
367
the yield can be improved by performing initial bilateral TAB or achieving a TAB
post-xation length of at least 3cm [6].
Histologically, the inammatory inltrate in GCA is predominantly composed of
histiocytes/macrophages and CD4+ lymphocytes, with variable involvement of the
three arterial layers, often showing only segmental inammation in parts of the arterial wall (Fig.16.1). The lymphocyte population usually includes lesser numbers of
CD8+ cytotoxic and CD20+ B cells. Focal fusion of histiocytes and formation of
multinucleate giant cells are seen, but these are not required for the diagnosis. The
inammation typically results in breaks, segmental loss and reduplication of the elastic lamina, best seen on elastin stain. This may lead to critical luminal narrowing and
aneurysm formation. Following the active phase inammatory cell inltrates may be
absent but intimal-medial scarring and injury to the elastic lamina often remains [2].
The European League Against Rheumatism (EULAR) taskforce for imaging in
large vessel vasculitis guideline recommends temporal artery ultrasound as the

368
https://t.me/medicina_free
M. Rischmueller et al.
rst- line imaging modality for predominantly cranial GCA in centres where experience is at hand, as the test is non-invasive, immediate and cost effective, and in some
centres, is replacing the need for TAB [7]. The temporal artery ultrasound nding of
a non-compressible halo sign, caused by oedema of the vessel wall, has a reported
sensitivity between 77 and 79% and specicity between 96 and 100% for the diagnosis of GCA. This investigation is dependent on training and expertise of the
sonographer, however, and the ability to detect a halo sign declines rapidly after the
initiation of glucocorticoids, with sensitivity falling to below 50% at 4days. For
conrmation of large vessel GCA not involving cranial vessels, other imaging techniques are required, which are also sensitive to glucocorticoid therapy. Highresolution MRI has the advantages of the absence of radiation, the contemporaneous
detection of structural lesions (such as vessel wall thickening and luminal stenosis/
occlusion), and contrast enhancement of the arterial wall presumed (but not proven)
to reect active inammation [7]. Compared with TAB, 18F-uorodeoxyglucose
PET combined with low dose ne cut computed tomography (18F-FDG-PET/CT)
performed within 72h of commencement of glucocorticoids had a sensitivity of
92%, specicity of 85%, negative predictive value of 98%, and identied patients
with aortitis, who require closer follow up for late complications such as aneurysm
development or aortic regurgitation. Cranial arteritis affects temporal, vertebral,
maxillary and occipital arteries, with vasculitis mimics including malignancies
found in 20% of patients [8].
Treatment of GCA consists of high dose glucocorticoids, usually 40–60 mg
prednisolone daily or 1mg/kg body weight, augmented by immediate intravenous
pulses of high dose methylprednisolone in the presence of ocular involvement.
Blindness is almost always irreversible, but is a rare occurrence after 2 weeks of
high dose glucocorticoids. Glucocorticoids are slowly tapered following normalisation of symptoms, CRP and ESR, usually commencing at around 4–6weeks, with
ongoing monitoring of symptoms and inammatory markers. Treatment with glucocorticoids typically continues between 18 and 24 months, with many requiring
long-term therapy. When studied in the context of clinical trials, only 15–20% of
patients achieve long-term remission, highlighting the need for alternative therapies.
Traditional disease modifying antirheumatic drugs (DMARDs) are not effective in GCA; treatment with methotrexate (MTX) leads to a signicant, though
modestly reduced risk of relapse and lower cumulative glucocorticoid doses
compared with placebo, however does not reduce the rate of drug-related adverse
events. Leunomide (LEF), azathioprine, cyclophosphamide (CYC), mycophenolate mofetil (MMF), and cyclosporin A (CyA) have not shown efcacy. Low
dose aspirin is recommended to prevent thrombotic complications, but clinical
evidence is lacking [9]. One year of treatment with tocilizumab (TCZ), a humanised monoclonal antibody targeting the IL-6 receptor (IL-6R) was shown in
clinical trials to be signicantly more likely to lead to sustained remission of
GCA than placebo, at just over half the cumulative glucocorticoid dose [10].
Aortic MRA abnormalities resolved in only one third of patients on TCZ, however, and a signicant relapse rate was observed after its cessation [11]. TCZ is

16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
nevertheless the rst drug to be licensed by the Food and Drug Agency (FDA),
the European Medicines Agency and Therapeutic Goods Administration for
GCA, and has paved the way for further clinical trials. Tumour necrosis factor
inhibitors (TNFi) are not effective for GCA, whereas a monoclonal antibody to
the p40 subunit common to both IL-12 and IL-23 (key cytokines regulating Th1
and Th17 differentiation, respectively) showed promise for refractory GCA in an
open-label prospective study. Other targets under evaluation include T cell costimulation, IL-1β, B cells, Janus kinases (JAK), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-17, and endothelin receptors. A lack of
reliable biomarkers which reect vascular inammation is an impediment to
individual patient management and drug development. Redirecting the focus of
diagnostic and therapeutic strategies from the extravascular/systemic disease
phase of the disease reected by raised CRP and ESR, to the vascular inammation phase, may ultimately improve disease outcomes [3].
369
16.3.2 Takayasu Arteritis
Takayasu arteritis (TAK, previously known as “pulseless disease”) is a granulomatous arteritis affecting the aorta and its main branches as well as the pulmonary
vasculature, causing aneurysm formation and tissue infarction. Histopathology is
similar to GCA with the presence of transmural lymphocytic inltration and multinucleated giant cells, but involvement of cranial vessels is not a feature, and patients
are typically women under 50years of age. TAK occurs across all races and geographic locations, with a higher incidence in Asians and South Americans [12].
The strongest genetic susceptibility locus for TAK is HLA-B∗52. Non-HLA susceptibility loci include Fc gamma receptor loci FCGR2A/FCGR3A, IL12B, and IL6
[13]. Early vascular lesions consist of T cells, natural killer cells, and macrophages.
Granuloma formation and giant cells can subsequently be found in the media of
elastic arteries. Late-stage (‘burnt out’) damage demonstrates extensive brosis and
intimal hyperplasia, which may lead to aneurysm formation or arterial stenosis
(Fig.16.2). In contrast to GCA, a pathogenic role for B cells has been suggested in
TAK by the identication of nonspecic polyclonal hypergammaglobulinemia, circulating anti-endothelial antibodies, increased numbers of circulating plasmablasts,
B cell inltration of aortic adventitia, and elevated serum levels of B cell-activating
factor in patients with active disease [13].
Patients usually present with symptoms of limb ischaemia, hypertension and/or
renal impairment. Signs on examination include differential brachial blood pressures, inability to palpate peripheral pulses, and subclavian, axillary, abdominal and
femoral bruits. Diagnosis may be conrmed by imaging of the aortic trunk and
vessels by MRI, PET or CT [7]. CRP and ESR are not always elevated. The
American College of Rheumatology classication criteria for TAK are shown in
Table16.3 [14].

370
ab
cd
https://t.me/medicina_free
M. Rischmueller et al.
Fig. 16.2 Takayasu arteritis. 18F-FDG-PET/CT showing increased radiotracer avidity associated
with the ascending aorta (a, b). Aortic wall showing patchy lymphocytic inammatory inltrate
within the media. Elsewhere there is evidence of dense brosis of the aortic wall with extensive
disruption of the elastic bre architecture (c, d)
Table 16.3 1990 criteria for the classication of Takayasu arteritis
1. Age at disease
onset ˂40years
2. Claudication of
extremities
3. Decreased brachial
Development of symptoms or ndings related to Takayasu arteritis
≤40years
Development and worsening of fatigue and discomfort in muscles of
one or more extremity while in use, especially the upper extremities
Decreased pulsation of 1 or both brachial arteries
a
[14]
artery pulse
BP difference
4.
Difference of >10mmHg in systolic blood pressure between arms
>10mmHg
5.
Bruit over
subclavian arteries or
Bruit audible on auscultation over 1 or both subclavian arteries or
abdominal aorta
aorta
6. Arteriogram
abnormality
Arteriographic narrowing or occlusion of the entire aorta, its primary
branches, or large arteries in the proximal upper or lower extremities,
not due to arteriosclerosis, bromuscular dysplasia, or similar causes;
changes usually focal or segmental
a
For purposes of classication, a patient shall be said to have Takayasu arteritis if at least 3 of these
6 criteria are present. The presence of any 3 or more criteria yields a sensitivity of 90.5% and a
specicity of 97.8%. BP = blood pressure (systolic; difference between arms).

16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
Glucocorticoids are the mainstay of treatment for TAK. CYC is usually used
initially in conjunction with high dose glucocorticoids for severe or organ-threatening disease. Conventional DMARDs have shown limited potential for steroid-sparing in uncontrolled series [12], yet treatment with leunomide led to a favourable
clinical response in 12 of 15 TAK patients with refractory disease [15]. A recent
literature review reported the efcacy of TNFi (mainly iniximab, IFX), with remission induction in 70–90% of TAK patients unable to achieve or maintain remission
with glucocorticoids and traditional immunosuppressants alone; over 40% of these
patients were able to discontinue glucocorticoids, while relapses were described in
nearly 40% [15]. As in GCA, IL-6 is highly expressed within inamed arteries in
TAK, and serum IL-6 levels correlate with disease activity. Several case series and
case reports suggested that TCZ may be effective for relapsing or refractory TAK,
but with mixed radiologic outcomes [12]. Other rare causes of aortitis, such as
relapsing polychondritis and Cogan’s syndrome, have also been reported to benet
from TNFi and TCZ [12]. Rituximab (RTX), a B-cell depleting monoclonal antibody targeting CD20, may be a potentially effective and safe therapeutic option in
patients with TAK refractory to the above immunosuppressive and biologic drugs,
but data does not support its use as rst line biologic therapy [15].
TAK is a chronic disease and inammatory activity tends to wax and wane, with
subclinical radiographic progression seen in more than two thirds of patients [12,
13], thus patients require long term monitoring and usually immunosuppression.
Stenting of arterial stenoses, particularly of renal arteries is often required, preferably when vessel inammation has been controlled. Collateral circulation may
compensate and improve painful limb claudication over time. In both TAK and
GCA, the late complications of aortic root dilatation with aneurysm formation and/
or aortic valve regurgitation, or abdominal aortic aneurysm, may require surgical
intervention. In patients with large vessel vasculitis (GCA or TAK), MRA, CT angiography (CTA) and/or ultrasound may be used for long-term monitoring of structural damage, particularly to detect stenosis, occlusion, dilatation and/or aneurysms.
The frequency of screening as well as the imaging method applied should be decided
on an individual basis [
7].
371
16.4 Medium Vessel Vasculitis
16.4.1 Polyarteritis Nodosa
Polyarteritis nodosa (PAN) is a rare necrotising vasculitis affecting medium-sized
or small muscular arteries. In contrast to microscopic polyangiitis (see below), PAN
is not associated with glomerulonephritis or vasculitis of the small vessels (arterioles, capillaries and venules). PAN occurs most commonly in middle-age with a
slight male predominance, with decreasing incidence concomitant with reduced
prevalence of hepatitis B virus (HBV) infection.

372
https://t.me/medicina_free
The aetiopathogenesis of classic PAN is not known, and pathway(s) leading to
necrotizing inammation of the blood vessels probably involve both the innate and
adaptive immune systems. Newly described loss of function mutations in genes
associated with autoinammatory diseases, such as CECR1 which codes for adenosine deaminase-2 (ADA2) can lead to a similar phenotype, implicating perturbation of leukocyte growth factors and endothelial instability [16]. HBV infection
accounts for 30% of cases previously diagnosed with PAN; vasculitis in this setting
has been shown to be caused by viral antigen-containing immune complex deposition on vascular walls with complement xation and vascular damage. Cutaneous
PAN is a designation given to patients presenting with necrotizing vasculitis conned to the skin, with occasional musculoskeletal features but no other systemic
involvement [16].
The characteristic presentation of PAN is with ischaemia and infarction of
numerous organs including the skin causing palpable purpura, livedo reticularis or
subcutaneous nodules, nervous system causing stroke or mononeuritis, kidneys
causing infarction, hypertension and renal failure, heart causing myocardial infarction, pericarditis, and congestive cardiac failure, gastrointestinal system causing
abdominal pain, infarction and haemorrhage, and testicles causing painful orchitis.
PAN rarely affects the lungs. Systemic symptoms such as fever, weight loss, arthralgia and myalgia are common.
Diagnosis is established by a combination of clinical features, biopsy (skin, testes, renal) and/or characteristic ndings on digital subtraction angiogram, which has
a better resolution than CTA.Histopathology reveals segmental transmural inammation of muscular arteries with evidence of necrosis and disruption of the internal
and external elastic lamina. The latter can lead to aneurysmal dilation. Characteristic
mesenteric or renal angiographic ndings are of multiple aneurysms and irregular
constrictions of larger vessels with occlusions of smaller vessels.
Isolated cutaneous PAN often responds to low dose glucocorticoids. Higher doses
of glucocorticoids are the mainstay of treatment for mild classic PAN in combination
with MTX, AZA, MMF or LEF as steroid-sparing agents. CYC is used in conjunction with glucocorticoids in moderate to severe cases. There is emerging evidence for
iniximab for refractory cases and patients with mutations causing ADA2 deciency,
and reports of benet with rituximab. Treated systemic PAN has a 5year survival rate
between 75 and 80%; untreated it is usually fatal. Treatment for HBV-associated
PAN is with anti-viral therapy coupled with short-term glucocorticoids, which can
lead to total remission of vasculitis with no evidence of recurrence.
M. Rischmueller et al.
16.4.2 Kawasaki Disease
Kawasaki disease (KD) is a paediatric vasculitis with coronary artery aneurysms
(CAA) as its main complication. It is most common in Japan and Asia, with reported
incidence rates of 265/100,000, most patients being between 6months and 5years
of age. The male:female ratio is approximately 1.5:1 [17].

16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
The aetiology of KD is unknown, with current consensus being that an infectious
trigger initiates an abnormal immune response involving innate and adaptive pathways in genetically predisposed children. Several genome-wide association studies
and case control studies have identied single nucleotide polymorphisms in genes
which code for proteins important in immune activation including FcgRIIa, CD40,
and BLK. Other identied pathways of potential importance include vascular endothelial growth factor (VEGF), angiopoietin, transforming growth factor-beta (TGF-β,
important in T cell activation and cardiovascular remodelling), and inositoltriphosphate 3-kinase (ITPKC, part of a transmembrane signalling pathway). ITPKC
inuences NLRP3 inammasome activation through intracellular calcium levels
leading to an increased IL-1β and IL-18 production [17]. Multiple potential infectious triggers have been implicated in KD pathogenesis. In the coronary arteries,
immune inltration of the arterial wall with neutrophils, CD8+ cytotoxic T cells,
Ig-A producing plasma cells, and macrophages have been found, accompanied by
pro-inammatory cytokines which vary in proportion and contribution over time [17].
The diagnosis of KD is based on the presence of clinical features of persistent
fever in combination with a rash, cervical lymphadenopathy, non-purulent conjunctival injection, changes of the lips and oral cavity (including strawberry tongue,
cracked lips, redness of the mucosae), and changes in extremities (swelling and
redness of the palms, desquamation in the subacute phase). There is no diagnostic
test for KD, and the diagnosis may be delayed or overlooked [17]. Coronary artery
lesions are diagnosed by echocardiography in the acute and subacute phases. Close
monitoring of CAA is important as ischemic symptoms or myocardial infarction
due to thrombosis or stenosis can occur, most likely in the largest, so-called giant
CAA.Apart from the presence of CAA, it is unclear whether KD causes an increased
cardiovascular risk due to the vasculitis itself [17].
Treatment consists of high dose intravenous immunoglobulin (IVIg) and is
directed at preventing the development of CAA.Unfortunately, 10–20% of patients
fail to respond to IVIg and these children need additional treatment with a second
dose of IVIg or glucocorticoids. Other immunosuppressants under investigation are
inhibitors of IL-1β, TNF and calcineurin. Initial addition of high-dose aspirin is
advised by the American Heart Association [
18].
373
16.5 Small Vessel Vasculitis
Small vessel vasculitides (SVV) are a group of relatively uncommon disorders
characterized by inammation of small intraparenchymal arteries, arterioles, capillaries, and venules which leads to vascular obstruction, tissue ischemia and
infarction. A complex overlapping set of clinical features involving different
organs and systems may occur. According to the 2012 Chapel Hill Consensus
Conference, SVV are divided into ANCA-associated vasculitides (AAV) and
immune complex vasculitides (ICV) [1]. AAV are necrotizing vasculitides frequently associated with proteinase 3 (PR3)-ANCA or myeloperoxidase

374
https://t.me/medicina_free
(MPO)-ANCA; ICV are characterized by wall deposits of immunoglobulin and
complement components, and include IgA vasculitis (IgAV), cryoglobulinaemic
vasculitis (CV), anti-glomerular basement membrane disease (anti-GBM), and
hypocomplementaemic urticarial vasculitis (HUV) [1].
M. Rischmueller et al.
16.5.1 Anti-neutrophil Cytoplasmic Antibody (ANCA)-
Associated Vasculitis (AAV)
ANCA are detected by indirect immunouorescence (IIF) of xed neutrophils, producing two main patterns: cytoplasmic (C-ANCA), usually caused by antibodies
targeting proteinase 3 (PR3), and perinuclear (P-ANCA), the typical pattern of antibodies targeting myeloperoxidase (MPO). A positive C-ANCA or P-ANCA on
screening IIF has low specicity and may be seen in other inammatory conditions
and healthy individuals. Conrmation by enzyme-linked immunosorbent assay is
required to conrm PR3 or MPO antibody specicity. There are three clinical subgroups of AAV: granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA, formerly
Churg-Strauss angiitis) and microscopic polyangiitis (MPA). These are rare and
potentially life-threatening multisystem autoimmune diseases.
Environmental factors play a role in pathogenesis, supported by variation in
geographical distribution, and relationship with exposure to silica, hydrocarbons
and various drugs. Infections such as Staphylococcus aureus have often been noted
to precede the onset or ares of AAV, with decreased relapse rates reported after
use of cotrimoxazole. Genetic associations include HLA-DRB1∗04, DPB1∗ 0401,
the proteinase 3 gene (PRTN3), and alpha-1-antitrypsin gene (SERPINA1) with
GPA, HLA-DRB4 with EGPA, and HLA-DRB1∗0901 with MPA.Toll-like receptor
9 (TLR 9) polymorphism is associated with PR3-ANCA but not MPO-ANCA vasculitis. Epigenetic factors include decreased histone demethylation at PR3 and
MPO loci [19]. A key role for neutrophils is indicated by amelioration of disease
in mouse models in the setting of neutrophil depletion, and abnormal neutrophil
extracellular traps containing PR3 and MPO have been demonstrated upon activating neutrophils with ANCA derived from human sera. Macrophages also have a
role in propagation of AAV [20]; the predominant effector cells implicated in
EGPA are eosinophils [21].
16.5.1.1 Granulomatosis withPolyangiitis (GPA)
The range of clinical presentations is broad and includes granulomatous inammation of upper and lower airways and vasculitis of small and medium vessels, of
which glomerulonephritis is common. Nasal symptoms include nasal obstruction,
bloody nasal discharge, epistaxis, chronic sinusitis, and saddle nose deformity.

16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
375
Subglottic stenosis, mastoiditis, otitis media, and orbital pseudotumor are seen less
commonly. Systemic features such as fever, arthralgia, and malaise may be absent
in the early localised phase. Pulmonary involvement occurs in up to 85% of patients
ranging from asymptomatic nodules to massive haemoptysis with respiratory failure. Radiologic features include pulmonary nodular inltrates, cavities, and bilateral ground glass opacities from pulmonary haemorrhage. Renal involvement in the
form of rapidly progressive glomerulonephritis is the presenting manifestation in
20% of patients, increasing to 80% over the disease course. Ocular involvement
occurs in 50% in the form of episcleritis, scleritis, and orbital disease. Cutaneous
manifestations are usually minor [22].
16.5.1.2 Eosinophilic Granulomatosis withPolyangiitis (EGPA)
This syndrome is characterized by eosinophil-rich granulomatous inammation
of the airways along with small- and medium-vessel vasculitis. Three different disease phases are usually described, namely, prodromal, eosinophilic, and vasculitic.
The main clinical feature in the prodromal stage is asthma (which may predate
vasculitis by years) and allergic rhinitis with or without polyposis. Upper airway
involvement is much milder than in GPA.The second phase is of peripheral and
tissue eosinophilia, which may be masked by glucocorticoid use for asthma.
Vasculitic manifestations occur in nerves, heart, lungs, GI tract, and kidneys. Skin
involvement is a dominant feature in the form of nodules; urticaria or ulceration.
Neurologic involvement occurs in 60–70% of patients in the form of multiple
mononeuropathies or symmetric polyneuropathy; ischemic optic neuropathy, cranial neuropathies, and stroke are less common. Cardiac involvement is seen in up to
20% of patients in the form of myocarditis, pericarditis, endocarditis, valvulitis, and
coronary vasculitis, and contributes to half the deaths. Renal involvement in the
form of small vessel vasculitis is less common than other AAVs [22].
16.5.1.3 Microscopic Polyangiitis (MPA)
MPA is a necrotising small-vessel AAV.Initially considered a part of PAN, it was
recognized as a distinct entity in 1994 [23]. The main manifestations are pauciimmune glomerulonephritis and pulmonary capillaritis. Granulomatous inammation is absent. Most patients present with rapidly progressive glomerulonephritis
and may be oliguric or anuric at the time of presentation, necessitating dialysis.
Lung haemorrhage is the most catastrophic manifestation seen in about 10% of
patients and is mostly associated with renal involvement. Most patients have constitutional symptoms, with fever, weight loss, arthralgia, and myalgia at the time of
presentation. Neurologic involvement is common in the form of mononeuritis multiplex, axonal sensorimotor neuropathy, or cranial nerve involvement. Skin manifestations include purpura, painful ulcers (frequently on the legs) and digital gangrene.

376
https://t.me/medicina_free
Ocular involvement includes scleritis, episcleritis, blepharitis, conjunctivitis, keratitis, uveitis, and retinal vasculitis [22].
Diagnosis of AAV is based on clinical features supported by positive ANCA and
biopsy of the involved organ wherever feasible. EGPA is associated with MPOANCA in approximately 50% of cases, whereas GPA and MPA are usually associated with PR3-ANCA. The presence of brinoid necrosis or crescentic
glomerulonephritis is highly suggestive of AAV.
Glucocorticoids and immunosuppressive drugs used in combination are the
mainstay of treatment, and have drastically changed the outcomes of these diseases,
which previously had a mortality rate of 90% at 2years. Remission induction in
organ- or life-threatening disease consists of CYC or RTX in combination with glucocorticoids. MMF was shown to be non-inferior to CYC for remission induction,
but resulted in higher relapse rates [24]. The PEXIVAS randomized controlled trial,
of 704 subjects demonstrated that plasma exchange does not reduce the risk of endstage renal disease or death in patients with severe AAV treated with glucocorticoids
combined with CYC or RTX induction. Compared with a standard dose, a reduced
steroid regimen did not substantially increase the risk of death or end-stage renal
disease and resulted in fewer serious infections [25]. Maintenance therapy following
induction is individualised, options including MTX, AZA, LEF, MMF, or RTX [21].
Mepolizumab is a humanized monoclonal antibody which binds free IL-5, an
essential cytokine for eosinophil development and proliferation, which is increased
in active EGPA.In a randomized controlled trial, mepolizumab proved effective in
prolonging remission in EGPA and allowed for reduced glucocorticoid use, leading
to FDA approval in 2017 [26]. IL-5 dependent cell proliferation and survival is
dependent on JAK signal transduction, as well as tyrosine kinases including Bruton
tyrosine kinase (BTK). Oral inhibitors of these kinases are available, and in addition, the complement component C5a is a potential therapeutic target in AAV.
M. Rischmueller et al.
16.5.2 Immune Complex Small Vessel Vasculitis
16.5.2.1 Immunoglobulin-A Vasculitis (IgAV)
Previously known as Henoch- Schönlein purpura, IgAVpredominantly affects capillaries, venules, or arterioles, with IgA1-dominant immune complex deposition. It is
the most common childhood vasculitis, affecting 10–20 children per 100,000 annually. More than 90% of patients are under 10years of age, with a mean age of
6 years; adults tend to have more severe disease. Clinical presentation of IgAV
comprises a characteristic tetrad of cutaneous palpable purpura, joint pain, colicky
abdominal pain, and renal involvement. Proposed triggers include upper respiratory
tract infections, medications, vaccinations, and (in adults) malignancies [27].
The skin rash consists of symmetric erythematous petechiae or papules on the
buttocks and lower extremities, which evolve to a typical palpable purpura [28].
Gastrointestinal symptoms occur in about 50% of cases. Abdominal pain is
Соседние файлы в папке Библиотека им академика М.И. Перельмана
